Ctrl

K

Palifermin

Class
Cytokines
Subclass
Polypeptides
Substance name
Palifermin
Brand names
Kepivance®
Common formulations
Powder for parenteral solution
Safety risks
Contraindications
A known hypersensitivity to palifermin or any of its components
Known or suspected malignant diseases of the head and neck region
Warnings and precautions
Fluid retention
•
Use caution with pre-existing cardiovascular conditions, such as congestive HF or severe hypertension.
Pulmonary edema
•
Use caution with pre-existing lung disease or a history of radiation therapy to the lungs.
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
•
Use acceptable. No dose adjustment required.
Renal replacement therapy
Any modality
•
Use acceptable. No dose adjustment required.
Hepatic impairment
Any severity
•
Use acceptable. No dose adjustment required.
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: B3
•
Use only if benefits outweigh potential risks. Evidence of fetal harm in animals.
Breastfeeding
Do not use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
•
Edema, ↑ serum amylase, ↑ serum lipase, change in taste, dysesthesia, fever, generalized pruritus, loss of appetite, pain, skin rash, skin erythema
Common 1-10%
•
Arthralgia
Unknown frequency
•
Palmar-plantar erythrodysesthesia, abdominal pain, headache, hypoesthesia, paresthesia, skin flushing, vomiting, tongue abnormality, vaginitis
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource